PUBLISHED MANUSCRIPTS - 2024

Moody R, Valentine WJ, Hoog M, Sharland H, Belger M. Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States. Journal of Managed Care & Speciality Pharmacy 2024; 30(2): 153-162.

Romano JGU, Malkin SJP, Hunt B. The Short-Term Cost-Effectiveness of a Fixed-Ratio Combination of Insulin Degludec and Aspart: A Cost of Control Analysis in Australia and India. Value in Health Regional Issues 2024; 41(5): 108-113.

Valentine WJ, Norrbacka K, Boye SK. Utilities for Complications Associated with Type 2 Diabetes: A Review of the Literature. Advances in Therapy 2024; 41(7): 2655-2681.

Altunkaya J, Li X, Adler A, Feenstra T, Fridhammar A, Keng MJ, Lamotte M, McEwan P, Nilsson A, Palmer AJ, Quan J, Smolen H, Tran-Duy A, Valentine WJ, Willis M, Leal J, Clarke P. Examining the Impact of Structural Uncertainty Across 10 Type 2 Diabetes Models: Results From the 2022 Mount Hood Challenge. Value in Health 2024; 27(10): 1338-1347.

Ramirez de Arellano A, Jakutis G, Hunt B. Cost analysis of patiromer vs sodium zirconium cyclosilicate for the treatment of hyperkalemia in Spain and the UK. Journal of Medical Economics 2024; 27(1): 1011-1017

Zhao T, Twe M, Feenstra T, Van Baal P, Willis M, Valentine WJ, Clarke PM, Hunt B, Altunkaya J, Tran-Duy A, Pollock RF, Malkin SJP, Nilsson A, McEwan P, Foos V, Leal J, Huang ES, Laiteerapong N, Lamotte M, Smolen H, Quan J, Martins L, Ramos M, Palmer AJ. The Impact of Unrelated Future Medical Costs on Economic Evaluation Outcomes for Different Models of Diabetes. Applied Health Economics and Health Policy 2024; 22(6): 861-869.

Alluhidan M, Alturaiki A, Alabdulkarim H, Aljehani N, Alghamdi EA, Alsabaan F, Alamri AA, Malkin SJP, Hunt B, Alhossan A, Al-Jedai A. Modeling the Clinical and Economic Burden of Therapeutic Inertia in People with Type 2 Diabetes in Saudi Arabia. Advances in Therapy 2024; 41(11): 4140-4152

PUBLISHED MANUSCRIPTS - 2023

Evans M, Chubb B, Malkin SJP, Berry S, Lawson J, Hunt B. Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11. Diabetes, Obesity and Metabolism 2023; 25(2): 491-500.

Evans M, Berry S, Nazeri A, Malkin SJP, Ashley D, Hunt B, Bain SC. The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes. Diabetes, Obesity and Metabolism 2023; 25(3): 639-648.

Moes RGJ, Huisman EL, Malkin SJP, Hunt B. Evaluating the Clinical and Economic Outcomes Associated with Poor Glycemic Control in People with Type 1 Diabetes in the Netherlands. Clinicoeconomics and Outcomes Research 2023; 15: 87-96.

Evans M, Berry S, Malkin SJP, Hunt B, Sharma A. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK. Diabetes Therapy 2023; 14(6): 1005-1021.

Viljoen A, Chubb B, Malkin SJP, Berry S, Hunt B, Bain SC. The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK. The European Journal of Health Economics 2023; 24(6): 895-907.

Berry S, Chubb B, Acs A, Falla E, Verma A, Malkin SJP, Hunt B, Palmer AJ. Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide. Journal of Medical Economics 2023; 26(1): 1019-1031.

Valentine WJ, Hoog MM, Mody R, Belger M, Pollock RF. Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States. Diabetes, Obesity and Metabolism 2023; 25(5): 1292-1300.

Ren H, Berry S, Malkin SJP, Hunt B, Bain S. Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy. BMJ Open. 2023; 13(9): e070473.

PUBLISHED MANUSCRIPTS - 2022

Franch-Nadal J, Malkin SJP, Hunt B, Martín V, Gallego Estébanez M, Vidal J. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials. Advances in Therapy 2022; 39(7): 3180-2198.

Malkin SJP, Carvalho D, Costa C, Conde V, Hunt B. The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal. Diabetology & Metabolic Syndrome 2022; 14(1): 32.

Yale JF, Osumili B, Mitchell BD, Hunt B, Sohi G, Jeddi M, Mojdami D, Valentine WJ. Evaluation of the cost and medical resource use outcomes associated with nasal glucagon versus injectable glucagon for treatment of severe hypoglycemia in people with diabetes in Canada: a modelling analysis. Journal of Medical Economics 2022; 25(1): 238-248.

Pollock RF, Norrbacka K, Boye KS, Osumili B, Valentine WJ. The PRIME type 2 diabetes model: A novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus. Journal of Medical Economics 2022; 25(1): 393-402.

Argüelles-Arias F, Bermejo F, Borrás-Blasco J, Domènech E, Sicilia B, Huguet JM, de Arellano AR, Valentine WJ, Hunt B. Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain. Therapeutic Advances in Gastroenterology 2022; 15: 17562848221086131.

Valentine W, Norrbacka K, Boye KS. Evaluating the Impact of Therapy on Quality of Life in Type 2 Diabetes: A Literature Review of Utilities Associated with Treatment-Related Attributes. Patient Related Outcome Measures 2022; 13: 97-111.

Osumili B, Artime E, Mitchell B, Rubio-de Santos M, Díaz-Cerezo S, Giménez M, Spaepen E, Sharland H, Valentine WJ. Cost of Severe Hypoglycemia and Budget Impact with Nasal Glucagon in Patients with Diabetes in Spain. Diabetes Therapy 2022; 13(4): 775-794.

Lambadiari V, Ozdemir Saltik AZ, de Portu S, Buompensiere MI, Kountouri A, Korakas E, Sharland H, Cohen O. Cost-Effectiveness Analysis of an Advanced Hybrid Closed-Loop Insulin Delivery System in People with Type 1 Diabetes in Greece. Diabetes Technology and Therapeutics 2022; 24(5): 316-323.

PUBLISHED MANUSCRIPTS - 2021

Roze S, Isitt JJ, Smith-Palmer J, Lynch P, Klinkenbijl B, Zammit G, Benhamou PY. Long-Term Cost-Effectiveness the Dexcom G6 Real-Time Continuous Glucose Monitoring System Compared with Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in France. Diabetes Therapy 2021; 12(1): 235-246.

Aksan A, Schoepfer A, Juillerat P, Vavricka S, Bettencourt M, Ramirez de Arellano A, Gavata S, Morin N, Valentine WJ, Hunt B. Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland. Advances in Therapy 2021; 38(1): 660-677. 

Smith-Palmer J, Leeuwenkamp OR, Virk J, Reed N. Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland. BMC Cancer 2021; 21(1): 10.

Jendle J, Ericsson Å, Gundgaard J, Møller JB, Valentine WJ, Hunt B. Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis. Diabetes Therapy 2021; 12(1): 373-388.

Capehorn M, Hallén N, Baker-Knight J, Glah D, Hunt B. Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting. Diabetes Therapy 2021; 12(2): 537-555.

Malkin SJP, Hunt B, Huisman EL, Grand TS, Chubb B. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials. Diabetes Research and Clinical Practice 2021; 175: 108759.

Hellgren M, Svensson AM, Franzén S, Ericsson Å, Gudbjörnsdottir S, Ekström N, Bertilsson R, Valentine W, Malkin S. The burden of poor glycaemic control in people with newly diagnosed type 2 diabetes in Sweden: A health economic modelling analysis based on nationwide data. Diabetes, Obesity and Metabolism 2021; 23(7): 1604-1613.

Aksan A, Beales ILP, Baxter G, de Arellano AR, Gavata S, Valentine WJ, Hunt B. Evaluation of the Cost-Effectiveness of Iron Formulations for the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease in the UK. ClinicoEconomics and Outcomes Research 2021; 13: 541-552. 

Carvalho D, Costa C, Hallén N, Baker-Knight J, Hunt B. A Long-term Cost-Effectiveness Analysis of Treatments for Type 2 Diabetes in Portugal: Once-Weekly Semaglutide 1 mg Versus Once-Daily Empagliflozin 25 mg. The Portuguese Journal of Endocrinology, Diabetes and Metabolism 2021; 16(1-2): 13-20.

PUBLISHED MANUSCRIPTS - 2020

Bain SC, Bekker Hansen B, Hunt B, Chubb B, Valentine WJ. Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK. Journal of Medical Economics 2020; 23(1): 98-105.

Gorgojo-Martínez JJ, Malkin SJP, Martín V, Hallén N, Hunt B. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. Journal of Medical Economics 2020; 23(2): 193-202.

Bain SC, Hansen BB, Malkin SJP, Nuhoho S, Valentine WJ, Chubb B, Hunt B, Capehorn M. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme. Diabetes Therapy 2020; 11(1): 259-277.

Vidal J, Malkin SJP, Hunt B, Martín V, Hallén N, Javier Ortega F. The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain. Diabetes Therapy 2020; 11(2): 509-521.

Cannon AJ, Bargiota A, Billings L, Hunt B, Leiter LA, Malkin S, Mocarski M, Ranthe MF, Schiffman A, Doshi A. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets. Journal of Managed Care & Specialty Pharmacy 2020; 26(2): 143-153.

Ali SN, Dang-Tan T, Valentine WJ, Hansen BB. Evaluation of the Clinical and Economic Burden of Poor Glycemic Control Associated with Therapeutic Inertia in Patients with Type 2 Diabetes in the United States. Advances in Therapy 2020; 37(2): 869-882.

Smith-Palmer J, Cerri K, Sbarigia U, Chan EKH, Pollock RF, Valentine WJ, Bonroy K. Impact of Stigma on People Living with Chronic Hepatitis B. Patient Related Outcome Measures 2020; 11: 95-107.

Johansen P, Chubb B, Hunt B, Malkin SJP, Sandberg A, Capehorn M. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK. Advances in Therapy 2020; 37(5): 2427-2441.

Hansen BB, Nuhoho S, Ali SN, Dang-Tan T, Valentine WJ, Malkin SJP, Hunt B. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. Journal of Medical Economics 2020; 23(6): 650-658.

Roze S, Isitt J, Smith-Palmer J, Javanbakht M, Lynch P. Long-term Cost-Effectiveness of Dexcom G6 Real-Time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K. Diabetes Care 2020; 43(10): 2411-2417. 

Jendle J, Ericsson Å, Ekman B, Sjöberg S, Gundgaard J, da Rocha Fernandes J, Mårdby AC, Hunt B, Malkin SJP, Thunander M. Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective. Journal of Medical Economics 2020; 23(11): 1311-1320.

Martín V, Vidal J, Malkin SJP, Hallén N, Hunt B. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting. Advances in Therapy 2020; 37(10): 4427-4445.

Igarashi A, Hunt B, Wilkinson L, Langer J, Pollock RF. Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis. Advances in Therapy 2020; 37(10): 4446-4457.

Pöhlmann J, Norrbacka K, Boye KS, Valentine WJ, Sapin H. Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy. The European Journal of Health Economics 2020; 21(8): 1179-1196.

Leeuwenkamp O, Smith-Palmer J, Ortiz R, Werner A, Valentine W, Blachier M, Walter T. Cost-effectiveness of Lutetium [ 177 Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France. Journal of Medical Economics 2020; 23(12): 1534-1541.

PUBLISHED MANUSCRIPTS - 2019

Viljoen A, Hoxer CS, Johansen P, Malkin S, Hunt B, Bain SC. Evaluation of the long‐term cost‐effectiveness of once‐weekly semaglutide versus dulaglutide for the treatment of type 2 diabetes mellitus in the UK. Diabetes, Obesity and Metabolism 2019; 21(3): 611-621.

Malkin S, Russel-Szymczyk M, Liidemann G, Volke V, Hunt B. Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia. Diabetes Therapy 2019; 10(1): 159-176.

Petitjean A, Smith-Palmer J, Valentine W, Tehard B, Roze S. Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France. BMC Cancer 2019; 19(1): 140.

Roze S, Smith-Palmer J, de Portu S, Delbaere A, de Brouwer B, de Valk HW. Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands. Clinicoeconomics and Outcomes Research 2019; 11: 73-82.

Jendle J, Pöhlmann J, de Portu S, Smith-Palmer J, Roze S. Cost-effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes. Diabetes Technology and Therapeutics 2019; 21(3): 110-118.

Billings LK, Mocarski M, Basse A, Hunt B, Valentine WJ, Jodar E. Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA. Clinicoeconomics and Outcomes Research 2019; 11: 271-282.

Smith-Palmer J, Takizawa C, Valentine W. Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada. BMC Urology 2019; 19(1): 19.

Johansen P, Hunt B, Iyer NN, Dang-Tan T, Pollock RF. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA. Advances in Therapy 2019; 36(5): 1190-1199.

Roze S, Smith-Palmer J, Delbaere A, Bjornstrom K, de Portu S, Valentine W, Honkasalo M. Cost-Effectiveness of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Patients with Poorly Controlled Type 2 Diabetes in Finland. Diabetes Therapy 2019; 10(2): 563-574.

Pöhlmann J, Russel-Szymczyk M, Holík P, Rychna K, Hunt B. Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi. Diabetes Therapy 2019; 10(2): 493-508.

Mezquita Raya P, Ampudia Blasco FJ, Hunt B, Martin V, Thorsted BL, Basse A, Price H. Evaluating the long-term cost-effectiveness of IDegLira for type 2 diabetes in Spain based on real-world clinical evidence. Diabetes, Obesity and Metabolism 2019; 21: 1349-1356.

Gæde P, Johansen P, Tikkanen CK, Pollock RF, Hunt B, Malkin SJP. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. Diabetes Therapy 2019; 10(4): 1297-1317.

Malkin SJP, Russel-Szymczyk M, Psota M, Hlavinkova L, Hunt B. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia. Advances in Therapy 2019; 36(8): 2034-2051.

Pöhlmann J, Mitchell BD, Bajpai S, Osumili B, Valentine WJ. Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis. Journal of Diabetes Science and Technology 2019; 13(5): 910-918.

Pollock RF, Valentine WJ, Marso SP, Andersen A, Gundgaard J, Hallén N, Tutkunkardas D, Magnuson EA, Buse JB; DEVOTE study group. Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). Applied Health Economics and Health Policy 2019; 17(5): 615-627.

Hunt B, Malkin SJP, Moes RGJ, Huisman EL, Vandebrouck T, Wolffenbuttel B. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. BMJ Open Diabetes Research and Care 2019; 7: e000705.

Pöhlmann J, Montagnoli R, Lastoria G, Parekh W, Markert M, Hunt B. Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy. Clinicoeconomics and Outcomes Research 2019; 11: 605-614.

Hunt B, Hansen BB, Ericsson Å, Kallenbach K, Ali SN, Dang-Tan T, Malkin SJP, Valentine WJ. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States. Advances in Therapy 2019; 36(12): 3483-3493.

Roze S, Smith-Palmer J, de Portu S, Özdemir Saltik AZ, Akgül T, Deyneli O. Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey. Diabetes Technology and Therapeutics 2019; 21(12): 727-735.

PUBLISHED MANUSCRIPTS - 2018

Dempsey M, Mocarski M, Langer J, Hunt B. IDegLira is associated with improved short-term clinical outcomes and cost savings compared with insulin glargine U100 plus insulin aspart in the U.S. Endocrine Practice 2018; 24(9): 796-804.

Dempsey M, Mocarski M, Langer J, Hunt B. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US. Journal of Medical Economics 2018; 21(11): 1110-1118.

Drummond R, Malkin S, Du Preez M, Lee XY, Hunt B. The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting. Diabetes, Obesity and Metabolism 2018; 20(10): 2371-2378.

Barnett AH, Arnoldini S, Hunt B, Subramanian G, Hoxer CS. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis. Diabetes, Obesity and Metabolism 2018; 20(8): 1921-1927.

Gyldmark M, Lampe K, Ruof J, Pöhlmann J, Hebborn A, Kristensen FR. Is the EUnetHTA HTA Core Model® fit for purpose? Evaluation from an industry perspective. International Journal of Technology Assessment in Health Care 2018; 34(5): 458-463.

Pollock RF, Muduma G. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. Advances in Therapy 2018; 35(12): 2128-2137.

Palmer AJ, Si L, Tew M, Hua X, Willis MS, Asseburg C, McEwan P, Leal J, Gray A, Foos V, Lamotte M, Feenstra T, O'Connor PJ, Brandle M, Smolen HJ, Gahn JC, Valentine WJ, Pollock RF, Breeze P, Brennan A, Pollard D, Ye W, Herman WH, Isaman DJ, Kuo S, Laiteerapong N, Tran-Duy A, Clarke PM. Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. Value in Health 2018; 21(6): 724-731.

Pollock RF, Valentine WJ, Marso SP, Gundgaard J, Hallén, Hansen LL, Tutkunkardas D, Buse JB, On behalf of the DEVOTE Study Group. DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK. Diabetes Therapy 2018; 9(3): 1217-1232.

Wilkinson L, Hunt B, Johansen P, Iyer NN, Dang-Tan T, Pollock RF. Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States. Diabetes Therapy 2018; 9(3): 951-961.

Wang L, Ye Q, Nielsen OK, Gadegaard A, Valentine WJ, Hunt B, Wang L. Evaluation of the Long-Term Impact of Improving Care for People with Type 2 Diabetes in China. Value in Health Regional Issues 2018; 15: 169-174.

Pollock RF, Chubb B, Valentine WJ, Heller S. Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach. Diabetes, Metabolic Syndrome and Obesity 2018; 11: 217-226.

Valentine WJ, Van Brunt K, Boye KS, Pollock RF. Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness Evaluation. Applied Health Economics and Health Policy 2018; 16(3): 357-366.

Pollock RF, Meckley LM. An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland. ClinicoEconomics and Outcomes Research 2018; 10: 223-229.

Lane WS, Weatherall J, Gundgaard J, Pollock RF. Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. Journal of Medical Economics 2018; 21(2): 144-151.

Jendle J, Ericsson Å, Hunt B, Valentine WJ, Pollock RF. Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden. Diabetes Therapy 2018; 9(1): 87-99.

PUBLISHED MANUSCRIPTS - 2017

Valentine WJ, Pollock RF, Saunders R, Bae J, Norrbacka K, Boye K. The PRIME Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus. Value in Health 2017; 20(7): 985-991.

Russell-Jones D, Heller S, Buchs S, Sandberg A, Valentine WJ, Hunt B. Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting. Diabetes, Obesity and Metabolism 2017; 19(12): 1773-1780.

Kvapil M, Prázný M, Holik P, Rychna K, Hunt B. Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic. Diabetes Therapy 2017; 8(6): 1331-1347.

Hunt B, McConnachie CC, Gamble C, Dang-Tan T. Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States. Journal of Medical Economics 2017; 20(11): 1117-1120.

Psota M, Psenkova MB, Racekova N, Ramirez de Arellano A, Vandebrouck T, Hunt B. Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak Health System. ClinicoEconomics and Outcomes Research 2017; 9: 749-762.

Pollock RF, Muduma G. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK. Expert Opinion on Drug Delivery 2017; 14(12): 1439-1446.

Hunt B, Glah D, van der Vliet M. Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands. Diabetes Therapy 2017; 8(4): 753-765.

Pollock RF, Muduma G. A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000. ClinicoEconomics and Outcomes Research 2017; 9: 475-483.

Hunt B, Ye Q, Valentine WJ, Ashley D. Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom. Diabetes Therapy 2017; 8(1): 129-147.

Roze S, de Portu S, Smith-Palmer J, Delbaere A, Valentine W, Ridderstrale M. Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump therapy in patients with type 1 diabetes in Denmark. Diabetes Research and Clinical Practice 2017; 128: 6-14.

Hunt B, Vega-Hernandez G, Valentine WJ, Kragh N. Evaluation of the long-term cost-effectiveness of liraglutide versus lixisenatide for treatment of type 2 diabetes mellitus in the UK setting. Diabetes, Obesity and Metabolism 2017; 19(6): 842-849.

Mezquita-Raya P, Ramírez de Arellano A, Kragh N, Vega-Hernandez G, Pöhlmann J, Valentine WJ, Hunt B. Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain. Diabetes Therapy 2017; 8(2): 401-415.

Hunt B, Mocarski, M, Valentine WJ, Langer J. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA. Advances in Therapy 2017; 34(4): 954-965.

Saunders R, Struys MMRF, Pollock RF, Mestek M, Lightdale JR. Patient safety during procedural sedation using capnography monitoring: a systematic review and meta-analysis. BMJ Open 2017; 7(6): e013402.

Hunt B, Mocarski, M, Valentine WJ, Langer J. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA. Journal of Medical Economics 2017; 20(7): 663-670.

Pollock RF, Tikkanen CK. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark. Journal of Medical Economics 2017; 20(3): 213-220.

Hunt B, Mocarski M, Valentine WJ, Langer J. IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting. Diabetes Therapy 2017; 8(3): 531-544.

Hunt B, Kragh N, McConnachie CC, Valentine WJ, Rossi MC, Montagnoli R. Long-Term Cost-Effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide. Clinical Therapeutics 2017; 39(7): 1347-1359.

PUBLISHED MANUSCRIPTS - 2016

Muduma G, Saunders R, Odeyemi I, Pollock RF. Systematic review and meta-analysis of tacrolimus versus ciclosporin as primary immunosuppression after liver transplant. PLoS ONE 2016; 11(11): e0160421.

Smith-Palmer J, Bae JP, Boye KS, Norrbacka K, Hunt B, Valentine W. Evaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes. ClinicoEconomics and Outcomes Research 2016; 8: 559-971.

Roze S, Duteil E, Smith-Palmer J, de Portu S, Valentine W, de Brouwer BF, Reznik Y, de Valk HW. Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands. Journal of Medical Economics 2016; 19(8): 742-749.

Bruhn D, Martin AA, Tavares R, Hunt B, Pollock RF. Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US. Journal of Medical Economics 2016; 19(7): 672-683.

Muduma G, Odeyemi I, Pollock RF. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK. Journal of Medical Economics 2016; 19(10): 995-1002.

Roze S, Smith-Palmer J, Valentine WJ, Cook M, Jethwa M, de Portu S, Pickup JC. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a UK perspective. Journal of Medical Economics 2016; 19(3): 236-242.

Roussel R, Martinez L, Vandebrouck T, Douik H, Emiel P, Guery M, Hunt B, Valentine WJ. Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics 2016; 19(2): 121-134.

Muduma G, Odeyemi I, Smith-Palmer J, Pollock RF. Review of the clinical and economic burden of antibody-mediated rejection in renal transplant recipients. Advances in Therapy 2016; 33(3): 345-356.

Roze S, Smith-Palmer J, Valentine W, Payet V, de Portu S, Papo N, Cucherat M, Hanaire H. Cost-effectiveness of sensor-augmented pump therapy with low glucose suspend versus standard insulin pump therapy in two different patient populations with type 1 diabetes in France. Diabetes Technology & Therapeutics 2016; 18(2): 75-84.

Muduma G, Odeyemi I, Pollock RF. Evaluating the cost-effectiveness of prolonged-release tacrolimus relative to immediate-release tacrolimus in liver transplant patients based on data from routine clinical practice. Drugs Real World Outcomes 2016; 3: 61-68.

PUBLISHED MANUSCRIPTS - 2015

Skovgaard R, Jon Ploug U, Hunt B, Valentine WJ. Evaluating the cost of bringing people with type 2 diabetes mellitus to multiple targets of treatment in Canada. Clinical Therapeutics 2015; 37(8): 1677-1688.

Muduma G, Odeyemi I, Pollock RF. Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK. Journal of Medical Economics 2015; 18(12): 1050-1059.

Muratalina A, Smith-Palmer J, Nurbekova A, Abduakhassova G, Zhubandykova L, Roze S, Karamalis M, Shamshatova G, Demessinov A, Dunne D’Agostino N, Lynch P, Larisa Yedigarova L, Klots M, Valentine W, Welsh J, Kaufman F. Project Baiterek: a patient access program to improve clinical outcomes and quality of life in children with type 1 diabetes in Kazakhstan. Value in Health Regional Issues 2015; 7: 74-79.

Roze S, Smith-Palmer J, Valentine W, de Portu S, Nørgaard K, Pickup JC. Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in type 1 diabetes: a systematic review. Diabetic Medicine 2015; 32(11): 1415-1424.

Smith-Palmer J, Boye KS, Perez-Nieves M, Valentine W, Bae JP. Cardiovascular risk profiles in Type 2 diabetes and the impact of geographical setting. Expert Review of Endocrinology & Metabolism 2015; 10: 243-257.

Goh SY, Tan SC, Lim LC, Chua B, Hunt B. Cost-effectiveness of switching from biphasic human insulin (BHI) to biphasic insulin aspart 30 (BIAsp-30) in type 2 diabetes patients with suboptimal glycaemic control in Singapore. Journal of Diabetology 2015; 1: 2.

Hunt B, Aguilar Garza JL, Enríquez Vázquez CJ, Jain P, Valentine WJ. Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico. Value in Health Regional Issues 2015; 8c: 20-27.

Valentine WJ, Curtis BH, Pollock RF, Van Brunt K, Paczkowski R, Brändle M, Boye KS, Kendall DM. Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK. Diabetes Research and Clinical Practice 2015; 109(1): 95-103.

Roze S, Saunders R, Brandt AS, de Portu S, Papo NL, Jendle J. Health-economic analysis of real-time continuous glucose monitoring in people with type 1 diabetes. Diabetic Medicine 2015; 32(5): 618-626.

Pollock RF, Kappelgaard AM, Seitz L. An analysis of product wastage arising from dosing increment granularity in four modern growth hormone administration devices. Expert Opinion on Drug Delivery 2015; 12(3): 353-360.

Pérez A, Mezquita Raya P, Ramírez de Arellano A, Briones T, Hunt B, Valentine WJ. Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin. Diabetes Therapy 2015; 6(1): 61-74.

Bargalló-Rocha JE, Lara-Medina F, Pérez-Sánchez V, Vázquez-Romo R, Villarreal-Garza C, Martínez-Said H, Shaw-Dulin RJ, Mohar-Betancourt A, Hunt B, Plun-Favreau J, Valentine WJ. Cost-effectiveness of the 21-gene breast cancer assay in Mexico. Advances in Therapy 2015; 32(3): 239-253.

Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infectious Diseases 2015; 15(1): 19.

PUBLISHED MANUSCRIPTS - 2014

Smith-Palmer J, Brändle M, Trevisan R, Orsini Federici M, Liabat S, Valentine W. Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. Diabetes Research and Clinical Practice 2014; 105(3): 273-284.

Saunders R, Lian J, Karolicki B, Valentine W. The cost-effectiveness and budget impact of stepwise addition of bolus insulin in the treatment of type 2 diabetes: evaluation of the FullSTEP trial. Journal of Medical Economics 2014; 17(12): 827-836.

Muduma G, Odeyemi I, Pollock RF. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability. Journal of Medical Economics 2014; 17(7): 520-526.

Giorda CB, Nicolucci A, Pellegrini F, Kristiansen CK, Hunt B, Valentine WJ, Vespasiani G. Improving quality of care in people with Type 2 diabetes through the Associazione Medici Diabetologi-annals initiative: a long-term cost-effectiveness analysis. Diabetic Medicine 2014; 31(5): 615-623.

Muduma G, Odeyemi I, Smith-Palmer J, Pollock RF. Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence. Patient Preference and Adherence 2014; 8: 391-399.

Smith-Palmer J, Kalsekar A, Valentine W. Influence of renal function on long-term graft survival and patient survival in renal transplant recipients. Current Medical Research and Opinion 2014; 30(2): 235-242.

PUBLISHED MANUSCRIPTS - 2013

Ericsson Å, Pollock RF, Hunt B, Valentine WJ. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. Journal of Medical Economics 2013; 16(12): 1442-1452.

Mezquita Raya P, Pérez A, Ramírez de Arellano A, Briones T, Hunt B, Valentine WJ. Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. Diabetes Therapy 2013; 4(2): 417-430.

Lamarsalle L, Hunt B, Schauf M, Szwarcensztein K, Valentine WJ. Evaluating the clinical and economic burden of healthcare-associated infections during hospitalization for surgery in France. Epidemiology and Infection 2013; 141(12): 2473-2482.

Rouzier R, Pronzato P, Chéreau E, Carlson J, Hunt B, Valentine WJ. Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Breast Cancer Research and Treatment 2013; 139(3): 621-637.

Pollock RF, Qian Y, Wisniewski T, Seitz L, Kappelgaard AM. Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis. Medical Devices: Evidence and Research 2013; 6: 107-114.

Vogel R, Smith-Palmer J, Valentine W. Evaluating the health economic implications and cost-effectiveness of dental implants: a literature review. International Journal of Oral & Maxillofacial Implants 2013; 28(2): 343-356.

Langer J, Hunt B, Valentine WJ. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. Journal of Managed Care Pharmacy 2013; 19(3): 237-246.

Pollock RF, Chilcott J, Muduma G, Valentine WJ. Laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes: a budget impact analysis in the UK. Journal of Medical Economics 2013; 16(2): 249-259.

Pollock RF, Muduma G, Valentine WJ. Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK. Diabetes, Obesity and Metabolism 2013; 15(2): 121-129.

Marty R, Roze S, Bresse X, Largeron N, Smith-Palmer J. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. BMC Cancer 2013; 13: 10.

PUBLISHED MANUSCRIPTS - 2012

Pollock RF, Curtis BH, Smith-Palmer J, Valentine WJ. A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin. Advances in Therapy 2012; 29(12): 1051-1066.

Roze S, Kurth H, Hunt B, Valentine W, Marty R. Evaluation of the cost per patient per injection of botulinum toxin A in upper limb spasticity: comparison of two preparations in 19 countries. Medical Devices: Evidence and Research 2012; 5: 97-101.

Blohmer JU, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, Benkow A, Valentine WJ, Eiermann W. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. Journal of Medical Economics 2013; 16(1): 30-40.

Smith-Palmer J, Fajardo-Montañana C, Pollock RF, Ericsson A, Valentine WJ. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics 2012; 15(5): 977-986.

Pollock RF, Curtis BH, Valentine WJ. A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States. Journal of Medical Economics 2012; 15(4): 766-775.

Valentine WJ, Jendle J, Saraheimo M, Thorsteinsson B, Pollock RF, Lammert M. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with type 1 diabetes treated with Insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. Diabetic Medicine 2012; 29(3): 303-312.

Davies MJ, Chubb BD, Smith IC, Valentine WJ. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabetic Medicine 2012; 29(3): 313-320.

PUBLISHED MANUSCRIPTS - 2011

Valentine WJ, Aagren M, Haglund M, Ericsson A, Gschwend MH. Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. Scandinavian Journal of Public Health 2011; 39(1): 79-87.

Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Clinical Therapeutics 2011; 33(11): 1698-1712.

Lippuner K, Pollock RF, Smith-Palmer J, Meury T, Valentine WJ. A Review of the Cost Effectiveness of Bisphosphonates in the Treatment of Post-Menopausal Osteoporosis in Switzerland. Applied Health Economics and Health Policy 2011; 9(6): 403-417.

Goodall G, Costi M, Timlin L, Reviriego J, Sacristán JA, Smith-Palmer J, Dilla T. Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus. Endocrinologia y Nutricion 2011; 58(7): 331-340.

Pollock RF, Erny-Albrecht KM, Kalsekar A, Bruhn D, Valentine WJ. Long-acting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetes. Current Diabetes Reviews 2011; 7(1): 61-74.

Pollock RF, Valentine WJ, Pilgaard T, Nishimura H. The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective. Journal of Medical Economics 2011; 14(1): 36-46.

PUBLISHED MANUSCRIPTS - 2010

Palmer JL, Beaudet A, White J, Plun-Favreau J, Smith-Palmer J. Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China. Advances in Therapy 2010; 27(11): 814-827.

Pollock RF, Valentine WJ, Goodall G, Brändle M. Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents: A long-term modelling study in Switzerland. Swiss Medical Weekly 2010; 140: w13103.

Smith-Palmer J, Curtis BH, Boye KS, Goodall G, Pillemer SR. Anti-CD3 monoclonal antibody treatment in newly diagnosed type 1 diabetes patients: a hypothetical modelling analysis. Diabetic Medicine 2010; 27(2): 189-196.

Valentine WJ, Pollock RF, Plun-Favreau J, White J. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes. Current Medical Research and Opinion 2010; 26(6): 1399-1412.

PUBLISHED MANUSCRIPTS - 2009

Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. Diabetes, Obesity and Metabolism 2009; 11(11): 1068-1079.

Lee KH, Seo SJ, Smith-Palmer J, Palmer JL, White J, Valentine WJ. Cost-Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly Controlled Type 2 Diabetes in South Korea. Value in Health 2009; 12(Suppl 3): S55-S61.

Smith-Palmer J, Kalsekar A, Boye K and Goodall G. The Impact of Obesity on Adverse Cardiovascular Outcomes in the General Population and in Patients with Type 2 Diabetes. Clinical Medicine, Endocrinology and Diabetes 2009; 2: 43-69.

Goodall G, Sarpong EM, Hayes C, Valentine WJ. The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC Endocrine Disorders 2009; 5: 9-19.

Pratoomsoot C, Smith HT, Kalsekar A, Boye KS, Arellano J, Valentine WJ. An estimation of the long-term clinical and economic benefits of insulin lispro in type 1 diabetes in the UK. Diabetic Medicine 2009; 26(8): 803-814.

Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P and Valentine WJ. Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. International Journal of Clinical Pharmacology and Therapeutics 2009; 47(8): 501-515.

Gschwend MG, Aagren M, Valentine WJ. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries. Journal of Medical Economics 2009; 12(2): 114-123.

Scherbaum WA, Goodall G, Erny-Albrecht KM, Massi-Benedetti M, Erdmann E, Valentine WJ. Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective. Cost Effectiveness and Resource Allocation 2009; 7(1): 9.

Brändle M, Goodall G, Erny-Albrecht KM, Erdmann E, Valentine WJ. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. Swiss Medical Weekly 2009; 139(11-12): 173-184.

PUBLISHED MANUSCRIPTS - 2008

Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, Pedersen O. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: Results and projections from the Steno-2 study. Diabetes Care 2008; 31(8): 1510-1515.

Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Advances in Therapy 2008; 25(8): 752-774.

Valentine WJ, Tucker D, Palmer AJ, Minshall ME, Foos V, Silberman C. Long-Term Cost-Effectiveness of Pioglitazone versus Placebo in Addition to Existing Diabetes Treatment: A US Analysis Based on PROactive. Value in Health 2008; 12(1): 1-9.

Valentine WJ, Goodall G, Aagren M, Nielsen S, Palmer AJ, Erny-Albrecht K. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. Advances in Therapy 2008; 25(6): 567-584.

Palmer JL, Goodall G, Nielsen S, Kotchie RW, Valentine WJ, Palmer AJ, Roze S. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. Current Medical Research and Opinion 2008; 24(5): 1417-1428.

Ray JA, Borker R, Barber B, Valentine WJ, Belozeroff V, Palmer AJ. Cost-Effectiveness of Early versus Late Cinacalcet Treatment in Addition to Standard Care for Secondary Renal Hyperparathyroidism in the USA. Value in Health 2008; 11(5): 800-808.

Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, Pongcharoensuk P, Ongphiphadhanakul B, Roze S, Valentine WJ, Palmer AJ. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand. Value in Health 2008; 11(S1): S43-S51.

Goodall G, Jendle JH, Valentine WJ, Munro V, Brandt AB, Ray JA, Roze S, Foos V, Palmer AJ. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naive type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting. International Journal of Clinical Practice 2008; 62(6): 869-876.

Minshall ME, Oglesby AK, Wintle ME, Valentine WJ, Roze S, Palmer AJ. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value in Health 2008; 11(1): 22-33.

Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, Rodby RA. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrology Dialysis Transplantation 2008; 23(4): 1216-1223.

Ali M, White J, Lee CH, Palmer JL, Smith-Palmer J, Fakhoury W, Valentine WJ. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia. J Med Econ 2008; 11(4): 651-670.